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ABSTRACT 
MicroRNAs (miRNAs) are short 19-24 nucleotide RNA molecules that have 
been shown to regulate the expression of other genes in a variety of eukaryotic 
systems. Abnormal expression of miRNAs has been observed in several human 
cancers, and furthermore, germline and somatic mutations in human miRNAs were 
recently identified in patients with chronic lymphocytic leukemia. Thus, human 
miRNAs can act as tumor suppressor genes or oncogenes, where mutations, 
deletions or amplifications can underlie the development of certain types of 
leukemia. In addition, previous studies have shown that miRNA expression profiles 
can distinguish among human solid tumors from different organs. Since a single 
miRNA can simultaneously influence the expression of two or more protein-coding 
genes, we hypothesized that miRNAs could be candidate genes for cancer risk. 
Research in complex trait genetics has demonstrated that genetic background 
determines cancer susceptibility or resistance in various tissues, such as colon and 
lung, of different inbred mouse strains. We compared the genome positions of 
mouse tumor susceptibility loci with those of mouse miRNAs. Here we report a 
statistically significant association between the chromosomal location of miRNAs 
and those of mouse cancer susceptibility loci that influence the development of solid 
tumors. Furthermore, we identified distinct patterns of flanking DNA sequences for 
several miRNAs located at or near susceptibility loci in inbred strains with different 
tumor susceptibilities. These data provide the first catalog of miRNA genes in inbred 
strains that could represent genes involved in the development and penetrance of 
solid tumors.  
INTRODUCTION 
The genetics of cancer penetrance is an evolving field that is leading to new 
strategies for cancer prevention and treatment. Susceptibility loci can influence not 
only cancer incidence and metastasis, but also the penetrance of other genetic 
disorders as well as susceptibility to infectious diseases (1-2, 
www.informatics.jax.org). The penetrance of tumor phenotypes results from the 
interaction between genetics and environment. The variability of environmental 
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factors and the genetic heterogeneity in human populations complicates the search 
for susceptibility loci. To control these factors, inbred mouse strains are useful 
models to search for allelic variants that confer susceptibility or resistance to 
different types of tumors (3). Quantitative trait loci (QTLs) analyses in mice have 
already identified chromosomal regions involved in cancer (3-5), and several protein-
coding genes have a proven role as cancer susceptibility loci (6-10). We suggest 
that a newly discovered family of noncoding genes, the miRNAs, could be 
responsible for susceptibility to solid tumors. 
Several papers have shown that miRNAs play an important role in different 
cancers, including B cell chronic lymphocytic leukemias (11), Burkitts lymphoma, 
colon cancer, lung cancer, and breast cancer (12-14). Furthermore, miRNA 
expression profiles can be used to classify human solid tumors and leukemias (10, 
15). Some miRNAs can downregulate large numbers of target mRNAs (16), and it is 
estimated that miRNAs could regulate 33% of the human genome (17). These 
targets may be oncogenes and tumor suppressor genes, supporting the idea that 
miRNAs could influence susceptibility and predispose individuals to different 
cancers. Because miRNAs are responsible for fine regulation of gene expression, 
“tuning” cellular phenotypes during delicate processes like development and 
differentiation, they represent a family of candidate genes for cancer susceptibility. 
Here, we evaluate the correlation of miRNAs with cancer susceptibility loci and 
identify miRNAs with a distinct pattern of flanking DNA regions in inbred mouse 
strains with diverse tumor phenotypes. Our work supports the hypothesis that 
miRNAs could represent a new family of susceptibility genes affecting the risk of 
cancer. 
 
RESULTS AND DISCUSSION 
 A genome-wide approach was used to investigate associations between 
miRNAs and mouse cancer susceptibility loci. This type of investigation was 
previously successful in identifying a significant association between the genomic 
position of human miRNAs and that of fragile sites (FRAs) and cancer-associated 
genomic regions (CAGRs) (18). 
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Compilation of known tumor susceptibility and modifier loci. We constructed a 
database that contained both susceptibility and modifier loci for 8 types of solid 
tumors in the mouse: bladder, colon, liver, lung, mammary gland, ovary, small 
intestine, and skin. The list was built by locus symbol, peak marker, chromosome 
(Chr), tissue, and strains. To obtain loci positions, we used the Mouse Genome 
Informatics Database (www.informatics.jax.org) and PubMed (www.pubmed.gov). 
Published data were evaluated to identify the peak location of each region (Fig. 1).  
 Several observations were derived from this analysis. First, Chr 4 had the 
largest number of susceptibility loci (13 total), followed by Chr 6 (12 loci). Second, 
Chr Y had no susceptibility loci, followed by Chr 14 (1 locus). The frequency 
distribution (Fig. 4, published as supporting information on the PNAS website) differs 
from a normal distribution, suggesting that genes predisposing to solid tumors are 
not distributed randomly within the genome, but tend to be concentrated on certain 
chromosomes. Third, Figure 1 shows that several susceptibility loci identified for the 
same organ overlap (such as for lung, Pas6 and Sluc2 on Chr 2, Pas1b and Sluc3 
on Chr 6, Par1 and Pas5a on Chr 11, Pas2 and Pas12 on Chr 17, and Pas3b and 
Sluc1 on Chr 19). Since these tumor susceptibility loci were discovered using 
different test conditions and strains in different laboratories and yet, reside in close 
proximity, they may be due to the same gene(s). Fourth, several susceptibility loci 
identified for different organs overlap (such as Hcs7/Hcif2 and Pas8 on Chr 1, Hcs3 
and Sluc12 on Chr 12, and the 9 loci on distal Chr 4). These findings suggest that 
genes controlling the integrity and/or homeostasis of multiple solid organs may be 
concentrated within the genome; there may be only one or multiple, closely linked 
genes in each of these regions. Alternatively, future studies that define more 
susceptibility loci in these and other organs may prove otherwise. 
Construction of the MUSMIRSUS Database. A total of 229 mouse miRNA gene 
locations were downloaded from the July 2005 miRNA registry website 
(microrna.sanger.ac.uk). We combined and compared the positions of mouse 
miRNAs with those of known susceptibility and modifier loci (www.ensembl.org); this 
ordered list was used to identify miRNAs that mapped at or near the peak of tumor 
loci (see Table 1 as an example). The database was named MUSMIRSUS, for Mus
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miRNA susceptibility and is contained in its entirety at 
www.kimmelcancercenter.org/siracusa/musmirsus.htm.  
A significant number of miRNAs are located close to tumor susceptibility loci.
To test hypotheses about the relationship of the incidence of miRNAs and their 
association with tumor susceptibility loci, we used the Random Effect Poisson 
Regression Model (18). For this analyses, the random effect used was chromosome, 
in that data within a chromosome is assumed correlated. Under this model, the 
number of miRNAs defined “events” and non-overlapping lengths of susceptibility 
regions defined “time”. The “length” of a susceptibility region was ±0.5 Mb if the gene 
is known, or estimated as ±5 Mb from the peak marker. Although a QTL need not be 
at the peak marker, the critical distance selected here covers the most likely interval. 
A miRNA was considered within a susceptibility region if it was located ±5 Mb from 
the peak location of a given locus. The fixed effect in the model consisted of an 
indicator variable for the presence/absence of each susceptibility region. We report 
the incidence rate ratio (IRR), 2-sided 95% confidence interval of the incidence rate 
ratio, and 2-sided p-values for testing the hypothesis that the incident rate ratio is 
1.0. An IRR significantly >1 indicates an increase in the number of miRNAs within a 
region. All statistical computations were completed using STATA v7.0. 
Overall, 96 miRNAs (41.9%) were located <5 Mb from the peak of the closest 
locus (or loci), representing a highly significant association between the incidence of 
miRNAs and tumor susceptibility regions. Specifically, the relative incidence of 
miRNAs occurred at a rate 1.5 times higher in susceptibility regions than non-
susceptibility regions (IRR=1.63, 95% CI {1.25, 2.14}, p<0.001). Therefore, miRNAs 
were found more often in (or near) susceptibility regions than in other areas of the 
genome (Fig. 2). The estimated rate of miRNAs is moderate in most chromosomes, 
but quite large in Chrs 2, 6, 7, 13, and especially Chr 12. Thus, a larger number of 
miRNAs than expected by chance occurs in these 5 chromosomes. Regardless of 
location, the model indicates that miRNAs are significantly more likely to reside 
within tumor susceptibility regions than outside them. In addition, a recent report 
suggests an association between the locations of mouse miRNAs and known sites 
of retroviral integration in mouse cancers (21).  
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Specific miRNAs as candidates for tumor susceptibility loci. Thirty-five of the 
229 miRNAs (15.3%) are located in close proximity (<2 Mb) to 24 susceptibility loci, 
some of which overlap with the same miRNA. For example, mir-30c-1 and mir-30e 
are 0.47 Mb distal to the mammary Mmtg2 locus, <2.5 Mb proximal to the colon 
Scc11 locus, and <3.6 Mb distal to the skin Skts7 locus on Chr 4. Similarly, mir-34a 
is 0.86 Mb distal to the small intestine Mom6 locus and <4.6 Mb distal to the ovary 
Gct1 locus on Chr 4. In addition, the bladder Bts2 locus and the lung Sluc7 locus 
overlap on Chr 6, and reside 0.4–4.8 Mb from a cluster of 6 miRNAs. These miRNAs 
are all <1 Mb from at least one susceptibility locus and also reside <5 Mb from a 
second susceptibility locus for a different organ. 
Eighteen mouse miRNAs (7.9%) localized near (<5 Mb) susceptibility loci 
correspond to human miRNAs located in human cancer associated regions 
(CAGRs) and fragile sites (FRAs) as previously reported (18). Some of these 18 
miRNAs are members of the let family (let-7a-1, let-7a-2, let-7d, let-7f-1), and 
reduced expression of let-7 miRNAs is associated with shortened postoperative 
survival in human lung cancer (22). Since the expression of let-7 and RAS protein 
are opposite in lung tumors versus normal tissue, RAS was shown to be regulated 
by the let-7 family (23). In fact, members of let-7 are located within 4 Mb of loci 
predisposing to lung cancer: let-7a-2 at Sluc10 on Chr 9, let-7f-2 at Slt5 on Chr X, 
and the cluster let-7d, let-7f-1, and let7a-1 at Sluc23 on Chr 13. The list of miRNAs 
at or near sites commonly altered in human cancers includes mir-215 and mir-194-1 
which are <0.17 kb from D1Mit208, a marker that defines the peak of the colon Scc3 
locus on Chr 1.  Homologous human miRNAs are located inside the FRA1H at Chr 
1q42.1; this fragile site is an HPV16 integration site involved in cervical cancer (18). 
In addition, mir-181b-2 and mir-199b are 3.3 Mb from the peak of the colon Scc2 
locus on Chr 2; homologous human miRNAs are located inside a CAGR at Chr 
9q33-34.1, which is a region commonly deleted in bladder cancer (18).  
 Some miRNAs can act as oncogenes or tumor suppressor genes (12, 14). If 
our hypothesis that miRNAs are candidates for tumor susceptibility genes is true, it 
is expected that some miRNAs will act cell autonomously and be abnormally 
expressed in cancer cells, whereas others will act non-cell autonomously to 
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influence cancer development (4). The expression of human homologs of candidate 
miRNAs for mouse tumor susceptibility loci was extensively reported. Nineteen of 
the 35 (54.3%) miRNAs located <2 Mb from the peak of a tumor susceptibility locus 
are abnormally expressed in at least one type of human solid cancer, with 
expression being significantly different from normal controls (19-20). Studies to 
discriminate differences in expression of candidate miRNAs between tumor 
susceptible and resistant strains are underway in our laboratories. 
Direct sequence screen of inbred strains. Discrete sequence alterations are 
frequently found in human cancers (21) and variation in the sequence of precursor 
miRNAs were identified in the normal human population (24) and in the germline of 
cancer patients (25). It was shown that a C to A polymorphism in the mature mir-
30c-2 sequence may alter target selection and thus exert profound biological effects 
(24). According to the miRanda algorithm, 10 of 12 predicted targets were not 
considered likely for the A-type variant mir-30c-2. Interestingly, the mouse homolog 
is located <1 Mb from the peak marker of the lung Lscc1 locus on Chr 1.  
We sequenced several miRNAs to determine if inbred strains with different 
tumor susceptibilities possessed unique alleles. Out of 229 miRNAs, 10% are 
located <1 Mb from the peak marker that defines 15 solid tumor susceptibility loci 
(see Table 1 as an example). In fact, 8 of these loci have >1 miRNA that lie within 
<1 Mb of their peak. Selection of miRNAs was based on criteria that included their 
proximity to susceptibility loci, the same miRNA being present in human CAGRs, 
and the available inbred strains. We sequenced 13 miRNAs (mir-1-1, mir-7-1, mir-
10a, mir-30c-2, mir-31, mir-34a, mir-133a-2, mir-196a-1, mir-207, mir-219-1, mir-
324, mir-346, mir-448) comparing susceptible, resistant, and/or common inbred 
strains. 
Genomic regions corresponding to each precursor miRNA were amplified 
including flanking 5’ and 3’ ends, because these regions are needed for miRNA 
expression (26). A highly conserved motif ~200 bp upstream of the miRNA stem-
loop was found in most independently (intergenic) transcribed nematode miRNAs 
(27). Moreover, independent transcription units in which the precursor miRNA is 
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sufficient for processing have been found in plants, with their promoter elements 
being located upstream of the stem-loop (28). 
 Seven of the 13 miRNAs showed sequence differences between inbred 
strains (Figs. 3 and 5-8, published as supporting information on the PNAS website). 
Figure 3A shows that the flanking region of mir-1-1 (near Sluc17) has 6 
substitutions upstream of the stem-loop in the susceptible O20 compared to the 
resistant B10.O20 strain. Figure 3B shows a deletion of TCCTTC for mir-219-1 
(near Pas2/Pas12) in the susceptible A/J compared with the resistant B6 strain. 
Furthermore, A/J carries a base substitution upstream and downstream of the stem-
loop. Figure 3C shows a dramatic difference upstream of the mir-196a-1 stem-loop 
(near Par1/Pas5a). The susceptible A/J carries the longest stretch of guanines 
compared with the resistant B6, SM/J, and Mus spretus strains. Together with 
substitutions, the data shows that there are four mir-196a-1 alleles. In addition, M. 
spretus has the only substitution found within a stem-loop structure.  
For mir-30c-2 (near Lscc1), the resistant AKR and B6 strains had different 
alleles with 6 substitutions and one insertion-deletion (in-del). The susceptible A/J 
strain has a third allele (Fig. 5). For mir-133a-2 (near Sluc17), a deletion of 
TATATGTA was found in the susceptible O20 compared to the resistant B10.O20 
strain. Furthermore, there are four substitutions upstream and two substitutions 
downstream of the mir-133a-2 stem-loop (Fig. 6). For mir-34a (near Mom6), 6 
substitutions and one in-del was found between the susceptible B6 and the resistant 
AKR strains. AKR and C3H had the same allele, B6, BALB and A/J had a second 
allele, and CAST had a third allele (Fig. 7). For mir-10a (near Par1/Pas5a), an in-del 
upstream of the stem-loop was detected in the susceptible A/J compared to the 
resistant B6 and SM/J strains (as well as BALB). M. spretus and CAST had 
additional unique alleles (Fig. 8).  
Computational prediction of miRNA promoters: Since only a few miRNA 
promoters have been identified experimentally (30-32), we used an automated 
computational pipeline to determine miRNA promoters, depending on their relative 
genomic location to the annotated protein-coding genes. The annotation system 
combines the genomic alignments of mRNAs and miRNAs with ab initio pol II 
Sevignani et al MiRNAs and cancer susceptibility loci in the mouse 9
promoter predictions of FirstEF (33). The genomic sequences and alignments of 
RefSeq mRNAs and known mRNAs were downloaded from the UCSC website 
(genome.ucsc.edu). Genomic alignments of miRNAs were determined by the BLAT 
program (34).  
For intragenic miRNAs that overlap with protein-coding genes and in the 
sense strand, the promoter of the host protein coding gene is considered as the 
promoter of the miRNA, since the ‘host’ transcript and miRNAs usually portray 
similar expression profiles indicating that these miRNAs are transcribed as part of 
long host transcription units (35-37). For the rest, we ran the FirstEF program on the 
5’ upstream region of all miRNAs, with cut-off values for posterior probabilities of 
donor, promoter, and first-exon of 0.4, 0.3, and 0.4, respectively, to predict the pol II 
promoters. Values of the posterior probabilities range from 0 to 1, where higher 
probabilities indicate a greater confidence that the corresponding predictions are 
correct (Table 3, published as supporting information on the PNAS website). 
Of 7 miRNAs that showed sequence differences between tumor susceptible 
and resistant strains, 5 miRNAs had changes within their predicted promoter regions 
(Fig. 3 and Table 3). The majority of alterations resided in the 5’ flanking and 
promoter regions (Figs. 3 and 5-8). Most variants were substitutions and in-dels; the 
in-dels were primarily in simple repeats. Since control of miRNA expression levels 
resides primarily in the 5’ flanking regions, the implications of these findings are that 
subtle changes in the nucleotide sequence of miRNA promoters could significantly 
affect expression of miRNA transcripts.  
MiRNAs in development, differentiation, and cancer. MiRNAs have significant 
roles in development and differentiation (38-40). Since a single miRNA can 
simultaneously target multiple genes, alterations in the amount and/or sequence of a 
mature miRNA can have significant effects on the expression of target genes. In 
addition, mutations in the promoter regions of miRNAs could affect the spatial, 
temporal, and/or absolute levels of miRNAs, without changing the sequence of the 
mature miRNA. The downstream consequences of such alterations would be 
manifest as changes in cellular physiology and phenotype. For example, if the fine-
tuning of gene expression controlled by miRNAs were subtly altered, leading to 
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enhanced rates of proliferation and/or decreased rates of apoptosis, such changes 
could significantly influence an individual’s risk of developing cancer over time. Our 
studies have shown that there is a statistically significant correlation between the 
map locations of mouse tumor susceptibility loci and the map locations of miRNAs. 
Furthermore, substitutions and in-dels were predominantly in promoter regions of 
several miRNAs between susceptible and resistant inbred strains. Taken together, 
this report supports the idea that miRNAs should be considered candidates for tumor 
susceptibility loci. MiRNAs could represent a new family of genes involved in the 
penetrance of human cancer and other diseases. Identification of such genes would 
be important to clarify the mechanisms involved in tumor initiation, growth, and 
progression as well as to reveal new markers for molecular diagnosis and novel 
targets for drug therapy. 
 
MATERIALS AND METHODS 
Mice: The A/J, AKR/J (AKR), BALB/cJ (BALB), C57BL/6J (B6), C3H/HeJ (C3H), 
CAST/Ei (CAST), M. spretus, and SM/J inbred strains were purchased from The 
Jackson Laboratory (Bar Harbor, ME) and maintained at the Thomas Jefferson 
University Animal Facility. O20/ADem and B10.O20/Dem mice are maintained at the 
Department of Laboratory Animal Resources of Roswell Park Cancer Institute. Both 
facilities are AAALAC accredited. 
Sequencing: High-molecular weight kidney DNA was isolated using the Qiagen 
DNeasy Tissue Kit (Valencia, CA). The genomic region of each miRNA was 
amplified and sequenced using primers listed in Table 2 (published as supporting 
information on the PNAS website). Sequence analyses were performed on genomic 
DNA from two mice from each strain. 
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FIGURE LEGENDS 
Fig. 1. Chromosomal positions of mouse tumor susceptibility loci and 
associated miRNAs. The MUSMIRSUS Database was used to identify miRNAs at 
or near the peak of mouse tumor susceptibility loci 
(www.kimmelcancercenter.org/siracusa/musmirsus.htm). Mouse chromosomes are 
shown with centromeres at the top. The map positions of mouse miRNAs (ovals) are 
compared with those of susceptibility loci (rectangles) for 8 types of solid tumors. 
MiRNAs <5 Mb from the peak of a susceptibility locus are shown. A large cluster of 
28 miRNAs on distal Chr 12 includes tissue-specific miRNA genes (mir-127, mir-
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136, mir-134, mir-154) that map to an imprinted region (29); most of these miRNAs 
reside near the lung Sluc12 locus.  
 
Fig. 2. Rates of miRNAs in susceptibility regions of mouse chromosomes. This 
plot illustrates the estimated rate of miRNAs in susceptibility regions versus non-
susceptibility regions by chromosome. For plotting purposes, rates of miRNAs within 
a region are computed as number of miRNAs/length of region (within each 
chromosome). Rates of miRNAs are plotted by chromosome and by susceptibility 
region status (susceptibility region versus not). The estimated length in Mb of the 
genome was based on Ensembl v33 (September 2005). There is a significant 
association (p<0.001) of the incidence of miRNAs near the peak of tumor 
susceptibility regions. 
Fig. 3. miRNA gene sequences are different between inbred strains. The 
nucleotide sequences of A) mir-1-1, B) mir-219-1, and C) mir-196a-1 are shown in 
the strains indicated in the top left boxes. Gray shading highlights sequence variants 
(substitutions and/or in-dels). The miRNA stem-loop sequences are in bold and the 
mature miRNA sequences are underlined. The tumor susceptibility loci that map 
close to each miRNA are shown in parentheses. For mir-1-1, several substitutions 
were found between the resistant B10.O20 and the susceptible O20 strain. The 
sequence of B10.O20 is identical to that of the B6 strain. For mir-219-1, a 6 bp in-del 
and two substitutions were found between the resistant B6 and the susceptible A/J 
strains. For mir-196a-1, four alleles were detected; the sequence of B6 is identical to 
that of the evolutionarily divergent CAST strain. The asterisk indicates the position of 
a substitution found within the mir-196a-1 stem-loop. Mir-196a-2 was also 
sequenced, because it has the same mature sequence as mir-196a-1, but is located 
on a different chromosome; mir-196a-2 had two substitutions upstream of the stem-
loop in M. spretus, but no difference was found between susceptible and resistant 
strains (data not shown).  
